Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03NZV
|
||||
| Former ID |
DIB000727
|
||||
| Drug Name |
SC-236
|
||||
| Synonyms |
SC-791; SC-872; COX-2 inhibitors (anticancer), Pfizer; COX-2 inhibitors (anticancer), Pharmacia
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Terminated | [547069] | ||
| Company |
GD Searle & Co
|
||||
| Formula |
C16H11ClF3N3O2S
|
||||
| Canonical SMILES |
n1n(c(cc1C(F)(F)F)c1ccc(cc1)Cl)c1ccc(S(=O)(=O)N)cc1
|
||||
| CAS Number |
CAS 170569-86-5
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Prostaglandin G/H synthase 2 | Target Info | Inhibitor | [527033] | |
| KEGG Pathway | Arachidonic acid metabolism | ||||
| Metabolic pathways | |||||
| NF-kappa B signaling pathway | |||||
| VEGF signaling pathway | |||||
| TNF signaling pathway | |||||
| Retrograde endocannabinoid signaling | |||||
| Serotonergic synapse | |||||
| Ovarian steroidogenesis | |||||
| Oxytocin signaling pathway | |||||
| Regulation of lipolysis in adipocytes | |||||
| Leishmaniasis | |||||
| Pathways in cancer | |||||
| Chemical carcinogenesis | |||||
| MicroRNAs in cancer | |||||
| Small cell lung cancer | |||||
| PathWhiz Pathway | Arachidonic Acid Metabolism | ||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.